Benjamin Saylor | Authors


Abiraterone Added to ADT and Docetaxel Prolongs PFS in De Novo mCSPC

June 09, 2021

In men with de novo metastatic castration-sensitive prostate cancer treated in the phase 3 PEACE-1 study, the addition of abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved radiographic progression-free surviva.